canadian liver foundation: fatty liver disease treatment approved in u.s. signals new era for canadians

in a groundbreaking development set to impact the medical landscape, madrigal pharmaceuticals announced the official release of its highly anticipated drug, rezdiffra, in the united states. the move follows the recent u.s. food and drug administration (fda) approval of rezdiffra, marking a significant advancement for individuals suffering from severe cases of metabolic dysfunction-associated steatohepatitis (mash), formerly non-alcoholic steatohepatitis (nash), a form of fatty liver disease . as the first medication designed specifically to target mash, rezdiffra represents a pivotal milestone in the medical community, offering new hope for patients not only in the united states but also extending to canada and beyond.

the accelerated approval for rezdiffra (scientifically termed resmetirom), in conjunction with diet and exercise for the treatment of adults, signals a turning point in the battle against mash, particularly for those confronting moderate-to-advanced liver scarring (fibrosis). the canadian liver foundation (clf) is closely monitoring developments related to rezdiffra, recognizing its future potential to open new avenues of treatment for patients across canada. the clf’s support for innovative treatments stems from our commitment to bringing liver research to life and enhancing both outcomes and quality of life for those affected by liver diseases.

mash, characterized by excess build-up of fat in the liver leading to inflammation and fibrosis, is the severe progression of metabolic dysfunction-associated liver disease (masld), formerly known as non-2022年世界杯预选赛阿根廷 liver disease. in canada, fatty liver disease affects approximately one in four canadians, or roughly nine million people, while mash impacts almost 1.5 million people in this country, with both forms of the disease on the rise. according to a study by the canadian nash network (2022), the frequency of fatty liver disease is projected to increase by 20 per cent through 2030, while cases of liver cirrhosis and hepatocellular carcinoma (liver cancer) related to mash are expected to see a 65 per cent increase in the next decade.